Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.

@article{Ali2013SystemicTF,
  title={Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.},
  author={F R Ali and John T. Lear},
  journal={The British journal of dermatology},
  year={2013},
  volume={169 1},
  pages={53-7}
}
Basal cell carcinoma (BCC) is the most common cancer in the U.K. and its incidence is increasing. Vismodegib, a hedgehog pathway inhibitor, has recently been licensed by the U.S. Food and Drug Administration for treatment of advanced BCC. Phase 2 trials have demonstrated efficacy in cases of locally advanced and metastatic BCC, as well as cases of hereditary basal cell naevus (Gorlin) syndrome. Side-effects are frequent and considerable and include myalgia, taste disturbance, alopecia, weight… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS